For the first time, significant numbers of patients with some solid cancer histologies can be successfully treated using immunological means. Progress in our understanding of immune activation, homeostasis and regulation has reached a “tipping point” that has enabled the development of multiple anti-tumor immune-based strategies. Adoptive cell transfer (ACT) of anti-tumor T cells after the depletion host immune cells causes objective regression in about 50% of the patients. Work on therapeutic cancer vaccines is intensive and will actively be discussed at the meeting. The challenge now is to control and direct the potent new weapons in at the immunotherapist’s disposal. This meeting will bring the key scientists who are securing the basic foundations of the new immunology and the translational immunotherapists who are pioneering strategies that objectively work in the clinic.
|Publication status||Published - 1 Mar 2007|
|Event||Keystone Symposia on Molecular and Cellular Biology: The Potent New Anti-Tumor Immunotherapies - Banff, Alberta, Canada|
Duration: 1 Mar 2007 → …
|Conference||Keystone Symposia on Molecular and Cellular Biology: The Potent New Anti-Tumor Immunotherapies|
|Period||1/03/07 → …|